In recent years, there have been major advances in
asthma both in the understanding of the pathophysiological
processes in the airways and in the effective use
of anti-inflammatory therapy [1, 2]. Examination of
bronchial mucosal biopsies obtained from the proximal
large airways reveals a cellular infiltrate typically of
eosinophils and lymphocytes, and epithelial damage and
desquamation [3], with the expression of several cytokines,
such as interleukins (IL-) 3, 4 and 5, and granulocytemacrophage
colony stimulating factor (GM-CSF), particularly
by lymphocytes and other cells types [4–6].
Several mediators, such as histamine, cysteinyl leukotrienes,
kinins, and eosinophil products such as eosinophil cationic
protein (ECP), have been detected in the asthmatic
airway. Priming for release of mediators, in particular
cysteinyl leukotrienes, especially from the eosinophil,
may occur [7]. Mediators may act on target cells within
the airways to induce features typical of asthma, such
as bronchoconstriction, mucus plugging, airway wall
oedema through microvascular leakage, eosinophil infiltration
and bronchial hyperresponsiveness [8].
Although many mediators are likely to play a role in
inducing these features, there is now compelling evidence
for an important role for cysteinyl leukotrienes
in asthma. This will be reviewed and the potential therapeutic
importance of inhibiting the effects of leukotrienes
In recent years, there have been major advances in
asthma both in the understanding of the pathophysiological
processes in the airways and in the effective use
of anti-inflammatory therapy [1, 2]. Examination of
bronchial mucosal biopsies obtained from the proximal
large airways reveals a cellular infiltrate typically of
eosinophils and lymphocytes, and epithelial damage and
desquamation [3], with the expression of several cytokines,
such as interleukins (IL-) 3, 4 and 5, and granulocytemacrophage
colony stimulating factor (GM-CSF), particularly
by lymphocytes and other cells types [4–6].
Several mediators, such as histamine, cysteinyl leukotrienes,
kinins, and eosinophil products such as eosinophil cationic
protein (ECP), have been detected in the asthmatic
airway. Priming for release of mediators, in particular
cysteinyl leukotrienes, especially from the eosinophil,
may occur [7]. Mediators may act on target cells within
the airways to induce features typical of asthma, such
as bronchoconstriction, mucus plugging, airway wall
oedema through microvascular leakage, eosinophil infiltration
and bronchial hyperresponsiveness [8].
Although many mediators are likely to play a role in
inducing these features, there is now compelling evidence
for an important role for cysteinyl leukotrienes
in asthma. This will be reviewed and the potential therapeutic
importance of inhibiting the effects of leukotrienes
การแปล กรุณารอสักครู่..

In recent years, there have been major advances in
asthma both in the understanding of the pathophysiological
processes in the airways and in the effective use
of anti-inflammatory therapy [1, 2]. Examination of
bronchial mucosal biopsies obtained from the proximal
large airways reveals a cellular infiltrate typically of
eosinophils and lymphocytes, and epithelial damage and
desquamation [3], with the expression of several cytokines,
such as interleukins (IL-) 3, 4 and 5, and granulocytemacrophage
colony stimulating factor (GM-CSF), particularly
by lymphocytes and other cells types [4–6].
Several mediators, such as histamine, cysteinyl leukotrienes,
kinins, and eosinophil products such as eosinophil cationic
protein (ECP), have been detected in the asthmatic
airway. Priming for release of mediators, in particular
cysteinyl leukotrienes, especially from the eosinophil,
may occur [7]. Mediators may act on target cells within
the airways to induce features typical of asthma, such
as bronchoconstriction, mucus plugging, airway wall
oedema through microvascular leakage, eosinophil infiltration
and bronchial hyperresponsiveness [8].
Although many mediators are likely to play a role in
inducing these features, there is now compelling evidence
for an important role for cysteinyl leukotrienes
in asthma. This will be reviewed and the potential therapeutic
importance of inhibiting the effects of leukotrienes
การแปล กรุณารอสักครู่..
